AKTX (Akari Therapeutics) Moat Score: 3/10 (As of Jul. 10, 2026)


AKTX Akari Therapeutics PLC AKTX
32 GF Score
Price $13.88
View Full Analysis

What is Akari Therapeutics Moat Score?

Akari Therapeutics AKTX +7.26% 32 Moat Score is 3 as of Jul. 10, 2026. GuruFocus rates AKTX with a GF Score™ of 32/100. Among 1,395 Biotechnology companies, Akari Therapeutics ranks better than 75.56% on this metric.

Akari Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Akari Therapeutics has No Moat: Akari Therapeutics has some intellectual property in the biotech space but faces intense competition and lacks significant market share or customer loyalty. The absence of strong regulatory barriers or cost advantages limits its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Akari Therapeutics might have No Moat - Very weak/transient advantages.

Akari Therapeutics  (NAS:AKTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Akari Therapeutics Moat Score Related Terms

AKTX vs MBRX, JAGX, ANEB: Moat Score Comparison

For the Biotechnology subindustry, Akari Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Moat Score falls into.


AKTX
32GF Score
Akari Therapeutics PLC AKTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Akari Therapeutics (AKTX) has a Moat Score of 3 as of Jul. 10, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Akari Therapeutics ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Akari Therapeutics' Moat Score too high?
Akari Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Akari Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Akari Therapeutics ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Moat Score compare to MBRX and JAGX?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #341 out of 1395 companies for Moat Score. This places Akari Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Akari Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akari Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Moat Score is 3 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for AKTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.88
Price